For 2024 argenx Expects To Spend Less Than $2B On Expenses And Under $500M In Net Cash For Operations

7/25/24 1:13:24 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ARGX alert in real time by email

FINANCIAL GUIDANCE

Based on its current operating plans, argenx expects its combined research and development and selling, general and administrative expenses in 2024 to be less than $2 billion. argenx updated its cash burn guidance and now expects to utilize less than $500 million of net cash1 in 2024 on anticipated operating expenses as well as working capital and capital expenditures.

Get the next $ARGX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ARGX

Date	Price Target	Rating	Analyst
11/12/2024	$697.00	Peer Perform → Outperform	Wolfe Research
11/5/2024	$715.00	Sector Perform → Sector Outperform	Scotiabank
11/1/2024	$515.00 → $650.00	Outperform → Neutral	Robert W. Baird
11/1/2024		Mkt Perform → Outperform	William Blair
10/10/2024	$605.00	Strong Buy	Raymond James
10/4/2024		Buy → Hold	Deutsche Bank
8/6/2024		Equal Weight → Overweight	Barclays
7/25/2024		Hold → Buy	Deutsche Bank

More analyst ratings

$ARGX
Financials

Live finance-specific insights

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
$573 million in third quarter global net product sales CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada Management to host conference call today at 1:30 PM CET (8:30 AM ET) Regulated information - Inside information October 31, 2024 7:00AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its third quarter 2024 financial results and provided a business update. "We delivered significant patient impact with VYVGART over the quarter, expanding our gMG footprint and delivering inn
10/31/24 2:00:00 AM ET
$ARGX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
October 24, 2024Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, October 31, 2024 at 1:30 PM CET (8:30 AM ET) to discuss its third quarter 2024 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation. Dial-in numbers: Belgium 32 800 50 201France
10/24/24 1:00:00 AM ET
$ARGX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
$478 million in second quarter global net product sales First CIDP patients treated with VYVGART® Hytrulo following June 21st FDA approval On track to begin four additional registrational studies across efgartigimod and empasiprubart by end of 2024 Management to host conference call today at 2:30 PM CET (8:30 AM ET) Regulated Information – Inside Information July 25, 2024 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its half year 2024 results and provided a second quarter business update. "We were excited to unveil our am
7/25/24 1:00:00 AM ET
$ARGX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$ARGX
Press Releases

Fastest customizable press release news feed in the world

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for efgartigimod SC to be first targeted approach for myositis patients who have limited treatment options November 20, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the decision to continue development of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in the ongoing Phase 2/3 ALKIVIA study in adults with idiopat
11/20/24 1:00:00 AM ET
$ARGX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – 7:30am ET Amsterdam, the Netherlands— argenx SE ((Euronext &, NASDAQ:ARGX) and Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that China's National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for VYVGART Hytrulo 1,000mg (5.6ml)/vial [efgartigimod alfa injection (subcutaneous injection)] for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo is approved for CIDP as a once weekly 30-to-90 second subcutaneous injection
11/11/24 7:30:00 AM ET
$ARGX
$ZLAB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
First and only NMPA-approved treatment for patients with CIDP in China Third approval for efgartigimod franchise in China demonstrating Zai Lab's deep expertise developing innovative treatments across a broad range of diseases Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) and argenx ((Euronext &, NASDAQ:ARGX) today announced that China's National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for VYVGART Hytrulo 1,000mg (5.6ml)/vial [Efgartigimod Alfa Injection (Subcutaneous Injection)] for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo is approved for CIDP as a once weekl
11/11/24 7:30:00 AM ET
$ARGX
$ZLAB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations

argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
January 16, 2023 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an extraordinary general meeting of shareholders will be held at 12:00 PM CET on Monday, February 27, 2023 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the extraordinary general meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration f
1/16/23 1:30:00 PM ET
$ARGX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
argenx Appoints Ana Cespedes to Board of Directors
December 12, 2022 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET, Ana Cespedes was appointed as non-executive director to its Board of Directors. Ana Cespedes brings robust experience across a broad range of critical areas for commercialization and access, as well as for organizational effectiveness. The voting result and all documents relating to the shareholders' meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings.
12/12/22 4:01:00 PM ET
$ARGX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
argenx Appoints Camilla Sylvest to Board of Directors
September 8, 2022 Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 6:30pm CET, Mrs. Camilla Sylvest was appointed as non-executive director to its Board of Directors. Mrs. Sylvest brings strong strategic and operational leadership in the scaling of global commercial pharmaceutical organizations with a specific focus on company culture and sustainability. The voting result and all documents relating to the shareholders' meeting will be available on the argenx website at www.arg
9/8/22 2:10:00 PM ET
$ARGX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

For 2024 argenx Expects To Spend Less Than $2B On Expenses And Under $500M In Net Cash For Operations

Chat with this insight

Recent Analyst Ratings for
$ARGX

$ARGX
SEC Filings

SEC Form 6-K filed by argenx SE

SEC Form 6-K filed by argenx SE

SEC Form 6-K filed by argenx SE

$ARGX
Financials

Live finance-specific insights

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update

argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024

argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

$ARGX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by argenx SE

Amendment: SEC Form SC 13G/A filed by argenx SE

SEC Form SC 13G/A filed by argenx SE (Amendment)

$ARGX
Market Insights

Live Market Insights

Argenx shares are trading higher after the company reported better-than-expected Q2 GAAP EPS and sales.